Market capitalization | $318.18m |
Enterprise Value | $334.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.38 |
P/S ratio (TTM) P/S ratio | 4.16 |
P/B ratio (TTM) P/B ratio | 32.32 |
Revenue growth (TTM) Revenue growth | 27.00% |
Revenue (TTM) Revenue | $76.45m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a NeuroPace Inc forecast:
7 Analysts have issued a NeuroPace Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 76 76 |
27%
27%
|
|
Gross Profit | 56 56 |
30%
30%
|
|
EBITDA | -21 -21 |
29%
29%
|
EBIT (Operating Income) EBIT | -23 -23 |
28%
28%
|
Net Profit | -28 -28 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Joel Becker |
Employees | 171 |
Founded | 1997 |
Website | www.neuropace.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.